Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

Inclusion Criteria: * APOE4 homozygotes * Willing and able to provide informed consent (or consent provided by a legally authorized representative) * Clinical diagnosis of mild cognitive impairment due to Alzheimer's disease or mild to moderate dementia due to Alzheimer's disease * Evidence of CSF biomarkers consistent with Alzheimer's disease * Serum neutralizing anti-AAVrh10 titer \<1:100 * No evidence of active infection of any type, including hepatitis virus (A, B, or C) or human immunodeficiency virus (HIV-1 and HIV-2) * Fertile or infertile individuals; it will be recommended that fertile individuals utilize barrier birth control measures to prevent pregnancy for the duration of the study * Individuals not receiving experimental medications or participating in another experimental protocol for at least 4 weeks prior to entry into the study * Participants who agree not to post their personal data related to the study on social media. Exclusion Criteria: * Individuals receiving systemic immunosuppressant or corticosteroid therapy other than protocol-specified, are receiving a monoclonal anti-amyloid therapy (example, Aduhelm™ (aducanumab), Leqembi™ (lecanemab-irmb) or unable to wash out from anti-coagulant medications. * Individuals who do not fit the American Journal of Neuroradiology recommendations for image-guided spinal procedures * Presence of other significant medical, psychiatric, or neurological conditions may disqualify the participant from participation in t…